1
|
Bailey H. Advances in emergency management of the critically Ill and injured. Curr Opin Crit Care 2024; 30:193-194. [PMID: 38690951 DOI: 10.1097/mcc.0000000000001153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2024]
Affiliation(s)
- Heatherlee Bailey
- Department of Emergency Medicine, VA Medical Center, 508 Fulton Street, Durham
| |
Collapse
|
2
|
Barletta JF, Palmieri TL, Toomey SA, Harrod CG, Murthy S, Bailey H. Management of Heat-Related Illness and Injury in the ICU: A Concise Definitive Review. Crit Care Med 2024; 52:362-375. [PMID: 38240487 DOI: 10.1097/ccm.0000000000006170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Abstract
OBJECTIVES The increasing frequency of extreme heat events has led to a growing number of heat-related injuries and illnesses in ICUs. The objective of this review was to summarize and critically appraise evidence for the management of heat-related illnesses and injuries for critical care multiprofessionals. DATA SOURCES Ovid Medline, Embase, Cochrane Clinical Trials Register, Cumulative Index to Nursing and Allied Health Literature, and ClinicalTrials.gov databases were searched from inception through August 2023 for studies reporting on heat-related injury and illness in the setting of the ICU. STUDY SELECTION English-language systematic reviews, narrative reviews, meta-analyses, randomized clinical trials, and observational studies were prioritized for review. Bibliographies from retrieved articles were scanned for articles that may have been missed. DATA EXTRACTION Data regarding study methodology, patient population, management strategy, and clinical outcomes were qualitatively assessed. DATA SYNTHESIS Several risk factors and prognostic indicators for patients diagnosed with heat-related illness and injury have been identified and reported in the literature. Effective management of these patients has included various cooling methods and fluid replenishment. Drug therapy is not effective. Multiple organ dysfunction, neurologic injury, and disseminated intravascular coagulation are common complications of heat stroke and must be managed accordingly. Burn injury from contact with hot surfaces or pavement can occur, requiring careful evaluation and possible excision and grafting in severe cases. CONCLUSIONS The prevalence of heat-related illness and injury is increasing, and rapid initiation of appropriate therapies is necessary to optimize outcomes. Additional research is needed to identify effective methods and strategies to achieve rapid cooling, the role of immunomodulators and anticoagulant medications, the use of biomarkers to identify organ failure, and the role of artificial intelligence and precision medicine.
Collapse
Affiliation(s)
- Jeffrey F Barletta
- Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale Campus, AZ
| | - Tina L Palmieri
- Burn Division, Department of Surgery, Shriners Hospitals for Children Northern California, Sacramento, CA
| | - Shari A Toomey
- Respiratory Department/Sleep Center, Carilion Clinic Children's Hospital, Roanoke, VA
| | | | - Srinivas Murthy
- Department of Pediatrics, BC Children's Hospital, Vancouver, BC, Canada
| | - Heatherlee Bailey
- Department of Emergency Medicine, Durham Veterans Affairs Medical Center, Durham, NC
| |
Collapse
|
3
|
Kaplan LJ, Bailey H, Pascual J, Chang CWJ, Cerra F. In Search of Clarity. Crit Care Med 2024; 52:343-345. [PMID: 38240515 DOI: 10.1097/ccm.0000000000005998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2024]
Affiliation(s)
- Lewis J Kaplan
- Division of Trauma, Surgical Critical Care and Emergency Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Heatherlee Bailey
- Department of Emergency Medicine, Durham VA Medical Center, Durham, NC
| | - Jose Pascual
- Division of Trauma, Surgical Critical Care and Emergency Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | | | - Frank Cerra
- Department of Surgery, University of Minnesota, Minneapolis, MN
| |
Collapse
|
4
|
Bailey H, Burlison H, Chandrasekar S, Wong C, Forshaw C, Duncan K. 30P Real-world disease characteristics and treatment patterns in patients with advanced non-small cell lung cancer and EGFR in Brazil and Taiwan. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00284-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
5
|
Bailey H, Lucherini S, Burlison H, Lam P, Vo L, Varol N. 96P Characteristics of patients with resectable non-metastatic non-small cell lung cancer treated with or without neoadjuvant therapy in Europe and Canada: A real-world survey. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00351-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
6
|
Abstract
Volunteerism to provide humanitarian aid occurs in response to disasters, crises, and conflict. Each of those volunteerism triggers engenders personal risk borne by the healthcare volunteer while rendering aid and merit specific evaluation. Factors that impact decision-making with regard to volunteering are personal, structural and crisis specific. Practical approaches to travel and on-scene safety benefit volunteers and should inform planning and preparation for volunteerism-driven travel. These approaches include planning for evacuation and potential rescue. These unique skills and approaches are generally not part of medical education outside of military service. The global medical community, including medical professional organizations, should embrace this opportunity to improve medical education and professional development to support humanitarian aid volunteerism. Disaster, crisis, or conflict-driven healthcare volunteerism highlights the core elements of altruism, dedication, and humanity that permeate clinician's drive to render aid and save lives.
Collapse
Affiliation(s)
- Heatherlee Bailey
- Department of Emergency Medicine, Durham VA Medical Center, 508 Fulton St., Durham, NC, 27705, USA.
| | - Lewis J Kaplan
- Division of Trauma, Surgical Critical Care and Emergency Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.,Surgical Services, Division of Surgical Critical Care, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA
| |
Collapse
|
7
|
Bailey H, Nasirova F, Sermon J, Rodrigues B, Khela K, Hall J, Last M, Penton J. 1232P Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Bailey H, Fandel AD, Silva K, Gryzb E, McDonald E, Hoover AL, Ogburn MB, Rice AN. Identifying and predicting occurrence and abundance of a vocal animal species based on individually specific calls. Ecosphere 2021. [DOI: 10.1002/ecs2.3685] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Affiliation(s)
- H. Bailey
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - A. D. Fandel
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - K. Silva
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - E. Gryzb
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - E. McDonald
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - A. L. Hoover
- Chesapeake Biological Laboratory University of Maryland Center for Environmental Science Solomons Maryland 20688 USA
| | - M. B. Ogburn
- Smithsonian Environmental Research Center 647 Contees Wharf Road Edgewater Maryland 21037 USA
| | - A. N. Rice
- Center for Conservation Bioacoustics Cornell Lab of Ornithology Cornell University Ithaca New York 14850 USA
| |
Collapse
|
9
|
Thoral PJ, Peppink JM, Driessen RH, Sijbrands EJG, Kompanje EJO, Kaplan L, Bailey H, Kesecioglu J, Cecconi M, Churpek M, Clermont G, van der Schaar M, Ercole A, Girbes ARJ, Elbers PWG. Sharing ICU Patient Data Responsibly Under the Society of Critical Care Medicine/European Society of Intensive Care Medicine Joint Data Science Collaboration: The Amsterdam University Medical Centers Database (AmsterdamUMCdb) Example. Crit Care Med 2021; 49:e563-e577. [PMID: 33625129 PMCID: PMC8132908 DOI: 10.1097/ccm.0000000000004916] [Citation(s) in RCA: 74] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Critical care medicine is a natural environment for machine learning approaches to improve outcomes for critically ill patients as admissions to ICUs generate vast amounts of data. However, technical, legal, ethical, and privacy concerns have so far limited the critical care medicine community from making these data readily available. The Society of Critical Care Medicine and the European Society of Intensive Care Medicine have identified ICU patient data sharing as one of the priorities under their Joint Data Science Collaboration. To encourage ICUs worldwide to share their patient data responsibly, we now describe the development and release of Amsterdam University Medical Centers Database (AmsterdamUMCdb), the first freely available critical care database in full compliance with privacy laws from both the United States and Europe, as an example of the feasibility of sharing complex critical care data. SETTING University hospital ICU. SUBJECTS Data from ICU patients admitted between 2003 and 2016. INTERVENTIONS We used a risk-based deidentification strategy to maintain data utility while preserving privacy. In addition, we implemented contractual and governance processes, and a communication strategy. Patient organizations, supporting hospitals, and experts on ethics and privacy audited these processes and the database. MEASUREMENTS AND MAIN RESULTS AmsterdamUMCdb contains approximately 1 billion clinical data points from 23,106 admissions of 20,109 patients. The privacy audit concluded that reidentification is not reasonably likely, and AmsterdamUMCdb can therefore be considered as anonymous information, both in the context of the U.S. Health Insurance Portability and Accountability Act and the European General Data Protection Regulation. The ethics audit concluded that responsible data sharing imposes minimal burden, whereas the potential benefit is tremendous. CONCLUSIONS Technical, legal, ethical, and privacy challenges related to responsible data sharing can be addressed using a multidisciplinary approach. A risk-based deidentification strategy, that complies with both U.S. and European privacy regulations, should be the preferred approach to releasing ICU patient data. This supports the shared Society of Critical Care Medicine and European Society of Intensive Care Medicine vision to improve critical care outcomes through scientific inquiry of vast and combined ICU datasets.
Collapse
Affiliation(s)
- Patrick J Thoral
- Department of Intensive Care Medicine, Amsterdam Medical Data Science (AMDS), Amsterdam Cardiovascular Sciences (ACS), Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, Vrije Universiteit, Universiteit van Amsterdam, Amsterdam, The Netherlands
| | - Jan M Peppink
- Department of Intensive Care Medicine, Amsterdam Medical Data Science (AMDS), Amsterdam Cardiovascular Sciences (ACS), Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, Vrije Universiteit, Universiteit van Amsterdam, Amsterdam, The Netherlands
| | - Ronald H Driessen
- Department of Intensive Care Medicine, Amsterdam Medical Data Science (AMDS), Amsterdam Cardiovascular Sciences (ACS), Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, Vrije Universiteit, Universiteit van Amsterdam, Amsterdam, The Netherlands
| | | | - Erwin J O Kompanje
- Department of Intensive Care Medicine, Erasmus MC, Rotterdam, The Netherlands
| | - Lewis Kaplan
- Division of Trauma, Surgical Critical Care and Emergency Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
- Executive Committee, Society of Critical Care Medicine, Mount Prospect, IL
| | - Heatherlee Bailey
- Department of Emergency Medicine, Durham VA Medical Center, Durham, NC
- Executive Committee, Society of Critical Care Medicine, Mount Prospect, IL
| | - Jozef Kesecioglu
- Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
- Executive Committee, European Society of Intensive Care Medicine, Brussels, Belgium
| | - Maurizio Cecconi
- Executive Committee, European Society of Intensive Care Medicine, Brussels, Belgium
- Department of Anaesthesia and Intensive Care, Humanitas Research Hospital, Humanitas University, Milan, Italy
| | - Matthew Churpek
- Department of Medicine, University of Wisconsin, Madison, WI
| | - Gilles Clermont
- Department of Critical Care Medicine, CRISMA Laboratory, University of Pittsburgh, Pittsburgh, PA
| | - Mihaela van der Schaar
- University of Cambridge, Cambridge, United Kingdom
- Alan Turing Institute, London, United Kingdom
| | - Ari Ercole
- Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom
- Data Science Section, European Society of Intensive Care Medicine, Brussels, Belgium
| | - Armand R J Girbes
- Department of Intensive Care Medicine, Amsterdam Medical Data Science (AMDS), Amsterdam Cardiovascular Sciences (ACS), Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, Vrije Universiteit, Universiteit van Amsterdam, Amsterdam, The Netherlands
- Executive Committee, European Society of Intensive Care Medicine, Brussels, Belgium
| | - Paul W G Elbers
- Department of Intensive Care Medicine, Amsterdam Medical Data Science (AMDS), Amsterdam Cardiovascular Sciences (ACS), Amsterdam Infection and Immunity Institute (AI&II), Amsterdam UMC, Vrije Universiteit, Universiteit van Amsterdam, Amsterdam, The Netherlands
- Data Science Section, European Society of Intensive Care Medicine, Brussels, Belgium
| |
Collapse
|
10
|
Kaplan L, Moheet AM, Livesay SL, Provencio JJ, Suarez JI, Bader MK, Bailey H, Chang CWJ. A Perspective from the Neurocritical Care Society and the Society of Critical Care Medicine: Team-Based Care for Neurological Critical Illness. Neurocrit Care 2021; 32:369-372. [PMID: 32043264 DOI: 10.1007/s12028-020-00927-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The Neurocritical Care Society and the Society of Critical Care Medicine have worked together to create a perspective regarding the Standards of Neurologic Critical Care Units (Moheet et al. in Neurocrit Care 29:145-160, 2018). The most neurologically ill or injured patients warrant the highest standard of care available; this supports the need for defining and establishing specialized neurological critical care units. Rather than interpreting the Standards as being exclusionary, it is most appropriate to embrace them in the setting of team-based care. Since there are many more patients than there are highly specialized beds, collaborative care and appropriate transfer agreements are essential in promoting excellent patient outcomes. This viewpoint addresses areas of clarification and emphasizes the need for collegiality and partnership in delivering the best specialty critical care to our patients.
Collapse
Affiliation(s)
- Lewis Kaplan
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA
| | - Asma M Moheet
- OhioHealth Riverside Methodist Hospital, Columbus, OH, USA
| | | | | | | | | | | | - Cherylee W J Chang
- Neuroscience Institute/Neurocritical Care, The Queen's Medical Center Neuroscience Institute, Honolulu, HI, 96813, USA.
- John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
| |
Collapse
|
11
|
Rahman S, Bailey H, Duncan K. Adequacy of clinical information on requests with reference to the Ottawa knee rules. Clin Radiol 2019. [DOI: 10.1016/j.crad.2019.09.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Bailey H, Lyubchich V, Wingfield J, Fandel A, Garrod A, Rice AN. Empirical evidence that large marine predator foraging behavior is consistent with area-restricted search theory. Ecology 2019; 100:e02743. [PMID: 31112299 DOI: 10.1002/ecy.2743] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 03/06/2019] [Accepted: 03/29/2019] [Indexed: 11/08/2022]
Abstract
When prey is patchily distributed, predators are expected to spend more time searching for food in proximity of recent prey captures before searching in other areas. This behavior, known as area-restricted search, results in predators remaining localized in areas where prey had been detected previously because of the higher probability of encountering additional prey. However, few studies have tested these predictions on marine species because of the difficulties of observing feeding behavior. In this study, we utilized passive acoustic detections of echolocating dolphins to identify foraging behavior. C-PODs (click train detectors) were deployed for two years with an acoustic recorder attached to the same mooring during the second year. The time series of feeding buzzes, indicative of foraging behavior, revealed that both bottlenose (Tursiops truncatus) and common dolphins (Delphinus delphis) were more likely to stay in the area longer when foraging activity was high at the beginning of the encounter. The probability of foraging was also higher following previous foraging activity. This suggests that dolphins were feeding on spatially patchy prey and previous foraging experience influenced their movement behavior. This is consistent with the predictions of area-restricted search behavior, a nonrandom foraging strategy.
Collapse
Affiliation(s)
- H Bailey
- Chesapeake Biological Laboratory, University of Maryland Center for Environmental Science, Solomons, Maryland, 20688, USA
| | - V Lyubchich
- Chesapeake Biological Laboratory, University of Maryland Center for Environmental Science, Solomons, Maryland, 20688, USA
| | - J Wingfield
- Chesapeake Biological Laboratory, University of Maryland Center for Environmental Science, Solomons, Maryland, 20688, USA
| | - A Fandel
- Chesapeake Biological Laboratory, University of Maryland Center for Environmental Science, Solomons, Maryland, 20688, USA
| | - A Garrod
- Chesapeake Biological Laboratory, University of Maryland Center for Environmental Science, Solomons, Maryland, 20688, USA
| | - A N Rice
- Bioacoustics Research Program, Cornell University, Ithaca, New York, 14850, USA
| |
Collapse
|
13
|
Favarato G, Bailey H, Burns F, Prieto L, Soriano-Arandes A, Thorne C. Migrant women living with HIV in Europe: are they facing inequalities in the prevention of mother-to-child-transmission of HIV?: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Eur J Public Health 2019; 28:55-60. [PMID: 28449111 DOI: 10.1093/eurpub/ckx048] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background In pregnancy early interventions are recommended for prevention of mother-to-child-transmission (PMTCT) of HIV. We examined whether pregnant women who live with HIV in Europe and are migrants encounter barriers in accessing HIV testing and care. Methods Four cohorts within the European Pregnancy and Paediatric HIV Cohort Collaboration provided data for pooled analysis of 11 795 pregnant women who delivered in 2002-12 across ten European countries. We defined a migrant as a woman delivering in a country different from her country of birth and grouped the countries into seven world regions. We compared three suboptimal PMTCT interventions (HIV diagnosis in late pregnancy in women undiagnosed at conception, late anti-retroviral therapy (ART) start in women diagnosed but untreated at conception and detectable viral load (VL) at delivery in women on antenatal ART) in native and migrant women using multivariable logistic regression models. Results Data included 9421 (79.9%) migrant women, mainly from sub-Saharan Africa (SSA); 4134 migrant women were diagnosed in the current pregnancy, often (48.6%) presenting with CD4 count <350 cells/µl. Being a migrant was associated with HIV diagnosis in late pregnancy [OR for SSA vs. native women, 2.12 (95% CI 1.67, 2.69)] but not with late ART start if diagnosed but not on ART at conception, or with detectable VL at delivery once on ART. Conclusions Migrant women were more likely to be diagnosed in late pregnancy but once on ART virological response was good. Good access to antenatal care enables the implementation of PMTCT protocols and optimises both maternal and children health outcomes generally.
Collapse
Affiliation(s)
- G Favarato
- Faculty of Population Health Sciences, UCL, UCL Great Ormond Street Institute of Child Health, London, UK
| | - H Bailey
- Faculty of Population Health Sciences, UCL, UCL Great Ormond Street Institute of Child Health, London, UK
| | - F Burns
- Research Department of Infection and Population Health, UCL, London, UK.,Royal Free London NHS Foundation Trust, London, UK
| | - L Prieto
- Department of Paediatrics, Hospital Universitario de Getafe, Madrid, Spain
| | - A Soriano-Arandes
- Paediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - C Thorne
- Faculty of Population Health Sciences, UCL, UCL Great Ormond Street Institute of Child Health, London, UK
| |
Collapse
|
14
|
Anderson JR, Mortimer K, Pang L, Smith KM, Bailey H, Hodgson DB, Shaw DE, Knox AJ, Harrison TW. Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial. PLoS One 2016; 11:e0160257. [PMID: 27560168 PMCID: PMC4999189 DOI: 10.1371/journal.pone.0160257] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 07/15/2016] [Indexed: 11/18/2022] Open
Abstract
Background Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that modulates inflammation in models of asthma. To determine whether pioglitazone improves measures of asthma control and airway inflammation, we performed a single-center randomized, double-blind, placebo-controlled, parallel-group trial. Methods Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks) or placebo. The primary outcome was the adjusted mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide (FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum supernatant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) levels. Study recruitment was closed early after considering the European Medicines Agency’s reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis. Results There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence interval [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analysis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group (-21 L/min, 95% CI -39 to -4, p = 0.02). Conclusions We found no evidence that treatment with 12 weeks of pioglitazone improved asthma control or airway inflammation in mild asthma. Trial Registration ClinicalTrials.gov NCT01134835
Collapse
Affiliation(s)
- J. R. Anderson
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - K. Mortimer
- Liverpool School of Tropical Medicine, Liverpool, UK and Aintree University Hospital NHS Foundation Trust, Fazakerley, United Kingdom
- * E-mail:
| | - L. Pang
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - K. M Smith
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - H. Bailey
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - D. B. Hodgson
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - D. E. Shaw
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - A. J. Knox
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| | - T. W. Harrison
- Nottingham Respiratory Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB, United Kingdom
| |
Collapse
|
15
|
Hammerly SC, Cerda DA, Bailey H, Johnson JA. A pedigree gone bad: increased offspring survival after using DNA‐based relatedness to minimize inbreeding in a captive population. Anim Conserv 2015. [DOI: 10.1111/acv.12247] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- S. C. Hammerly
- Department of Biological Sciences Institute of Applied Sciences University of North Texas Denton TX USA
| | - D. A. Cerda
- Department of Biological Sciences Institute of Applied Sciences University of North Texas Denton TX USA
| | | | - J. A. Johnson
- Department of Biological Sciences Institute of Applied Sciences University of North Texas Denton TX USA
| |
Collapse
|
16
|
Mallia-Milanes B, Dufour A, Bailey H, Meakin G, Leme A, Bolton C, Shapiro S, Overall C, Johnson S. S129 A two species proteomics approach to determine MMP-12 substrates in COPD. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
17
|
Mallia-Milanes B, Bailey H, Meakin G, Sheehan A, Knox A, Bolton C, Johnson S. P106 Tissue factor pathway inhibitor (TFPI) is cleaved by multiple proteases in COPD lungs to affect circulating TFPI levels. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Lanning ME, Wilder PT, Bailey H, Drennen B, Cavalier M, Chen L, Yap JL, Raje M, Fletcher S. Towards more drug-like proteomimetics: two-faced, synthetic α-helix mimetics based on a purine scaffold. Org Biomol Chem 2015. [PMID: 26204921 DOI: 10.1039/c5ob00478k] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Mimicry of two faces of an α-helix might yield more potent and more selective inhibitors of aberrant, helix-mediated protein-protein interactions (PPI). Herein, we demonstrate that a 2,6,9-tri-substituted purine is capable of disrupting the Mcl-1-Bak-BH3 PPI through effective mimicry of key residues on opposing faces of the Bak-BH3 α-helix.
Collapse
Affiliation(s)
- M E Lanning
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine St., Baltimore, MD 21201, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Anderson J, Yoshizawa C, Tan V, Bailey H, Tsiatis A, Bonham M, Sing A, Shak S, Baehner F. P034 Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer. Breast 2015. [DOI: 10.1016/s0960-9776(15)70084-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Tan V, Lu R, Tharayanil A, Anderson J, Tsiatis A, Bailey H, Bonham M, Pingitore A, Shak S, Baehner F. P032 Central lab HER2 testing by RT-PCR, IHC and FISH in locally HER2-Neg, ER+ IBC with in situ carcinoma. Breast 2015. [DOI: 10.1016/s0960-9776(15)70082-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-271. [PMID: 25214542 PMCID: PMC6267863 DOI: 10.1093/annonc/mdu450 10.1097/pai.0000000000000594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 08/28/2014] [Indexed: 04/29/2024] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| |
Collapse
|
22
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2014; 26:259-71. [PMID: 25214542 DOI: 10.1093/annonc/mdu450] [Citation(s) in RCA: 1861] [Impact Index Per Article: 186.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| | | |
Collapse
|
23
|
Tan V, Bailey H, Anderson J, Rothney M, Baehner F, Sing A. The 12-Gene DCIS Score Assay and Quantitative Gene Expression for ER, PR, and HER 2: Experience With 3045 Patients. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Sing A, Tan V, Bailey H, Anderson, J, Rothney M, Baehner F. The 12-Gene Dcis Score Assay and Quantitative Er, Pr, and Her2 Across Histologic Subtypes: Experience in the First 2 Years. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
John M, Knox AJ, McKeever TM, Meakin G, Bailey H, Cockcroft JR, Shale DJ, Harrison TW, Bolton CE. S27 The effects of statin therapy on inflammatory markers in patients with copd: a double blind randomised controlled trial. Thorax 2013. [DOI: 10.1136/thoraxjnl-2013-204457.34] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Arnold S, Bailey H, Bates G, Bell V, Brumbelow R, Chunn M, Coxon A, Crouse C, Djafari, Duke J, Ganeshram. Improvement Strategies to Reduce 30-Day Heart Failure Readmissions. Heart Lung 2013. [DOI: 10.1016/j.hrtlng.2013.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
27
|
Shander A, Walsh C, Bailey H, Cromwell C. Acquired hemophilia presenting as profound hematuria: evaluation, diagnosis, and management of elusive cause of bleeding in the emergency department setting. J Emerg Med 2013; 45:e1-6. [PMID: 23643238 DOI: 10.1016/j.jemermed.2012.11.108] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 11/04/2012] [Indexed: 10/26/2022]
Abstract
BACKGROUND There are numerous causes of bleeding that may present to the Emergency Department (ED). Although rare, acquired hemophilia is a potentially life-threatening bleeding disorder, with reported mortality rates ranging from 6% to 8% among patients who received proper diagnosis and treatment. Approximately two thirds of patients with this condition will present with major bleeding, the magnitude of which may necessitate urgent evaluation and care. OBJECTIVES The aim of this article is to provide an overview of the evaluation, differential diagnosis, and management of acquired hemophilia for the emergency physician. CASE REPORT A case report of a patient who presented to the ED with gross hematuria secondary to undiagnosed acquired hemophilia is described to facilitate a review of the laboratory evaluation, differential diagnosis, and treatment of acquired hemophilia. CONCLUSION Patients with acquired hemophilia-related bleeding may present to the ED for care, given the often serious nature of their bleeding. Delayed diagnosis may postpone the initiation of targeted, effective treatments for achieving hemostasis, with potentially catastrophic consequences, particularly in patients who require emergent invasive procedures. Recognition of the potential for an underlying bleeding disorder and subsequent consultation with a hematologist are critical first steps in effectively identifying and managing a patient with acquired hemophilia who presents with bleeding.
Collapse
Affiliation(s)
- Aryeh Shander
- Department of Anesthesiology and Critical Care Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey 07631, USA
| | | | | | | |
Collapse
|
28
|
Blanco GS, Morreale SJ, Bailey H, Seminoff JA, Paladino FV, Spotila JR. Post-nesting movements and feeding grounds of a resident East Pacific green turtle Chelonia mydas population from Costa Rica. ENDANGER SPECIES RES 2012. [DOI: 10.3354/esr00451] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
29
|
Was CA, Dunlosky J, Bailey H, Rawson KA. The unique contributions of the facilitation of procedural memory and working memory to individual differences in intelligence. Acta Psychol (Amst) 2012; 139:425-33. [PMID: 22321455 DOI: 10.1016/j.actpsy.2011.12.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Revised: 12/21/2011] [Accepted: 12/31/2011] [Indexed: 11/29/2022] Open
Abstract
Individual differences in working memory account for a substantial portion of individual differences in complex cognitive processes (e.g., comprehension) and fluid intelligence. However, a large portion of the variance in fluid intelligence and comprehension is unexplained. The current investigation was conducted to evaluate whether individual differences in the facilitation of procedural memory accounts for unique variance in intelligence not accounted for by working memory. To measure variability in the facilitation of procedural memory, we used a task that required participants to first classify exemplars of two categories; facilitation was then operationalized by subsequent improvements in the speed of classifying new exemplars from those categories (i.e., an operation-specific memory procedure). Three measures of each focal construct (facilitation in procedural memory, working memory, comprehension and fluid intelligence) were administered to 256 participants. We used structural equation modeling to examine the relationships among these latent variables. Working memory did account for variance in fluid intelligence and comprehension, but most important, individual differences in facilitation of procedural memory accounted for unique variance in fluid intelligence and comprehension.
Collapse
Affiliation(s)
- C A Was
- Kent State University, Kent, OH 44242, USA.
| | | | | | | |
Collapse
|
30
|
Oroz C, Bailey H, Hollows K, Lee J, Mullan H, Theobald N. A national audit on the management of pelvic inflammatory disease in UK genitourinary medicine clinics. Int J STD AIDS 2012; 23:53-4. [PMID: 22362690 DOI: 10.1258/ijsa.2011.011183] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The prompt and effective treatment of pelvic inflammatory disease (PID) may reduce the risk of complications such as infertility, ectopic pregnancy and pelvic pain. We conducted a national audit to investigate the treatment of women diagnosed with PID and associated rates of partner notification in genitourinary (GU) medicine clinics during 2008 and compared our results with the British Association of Sexual Health and HIV (BASHH) 2005 national guideline. Among a total of 1,105,587 female attendees, national data showed 18,421 cases of PID diagnosed in GU medicine clinics, giving an incidence of 167 cases per 10,000 attendences. We audited a national sample of 1132 PID cases for review. Of those, 504 (44.5%) received a recommended treatment regimen and 447 (39%) of named male contacts were treated. Adherence to recommended treatment and partner notification did not reach national standards.
Collapse
Affiliation(s)
- C Oroz
- Department of GU Medicine, Chalmers Sexual Health Clinic, Edinburgh
| | - H Bailey
- Department of Sexual Health, Wrexham Maelor Hospital, Wrexham
| | - K Hollows
- Department of GU Medicine, Stoke-on-Trent
| | - J Lee
- Josephine Butler Centre for Sexual Health, Clayton Hospital, Wakefield
| | - H Mullan
- West Hertfordshire Hospitals NHS Trust, Watford General Hospital, Watford
| | - N Theobald
- St Stephen's Centre, Chelsea and Westminster, London, UK
| |
Collapse
|
31
|
|
32
|
|
33
|
|
34
|
|
35
|
|
36
|
|
37
|
|
38
|
Shillinger GL, Swithenbank AM, Bograd SJ, Bailey H, Castelton MR, BP W, Spotila JR, Paladino FV, Piedra R, Block BA. Identification of high-use internesting habitats for eastern Pacific leatherback turtles: role of the environment and implications for conservation. ENDANGER SPECIES RES 2010. [DOI: 10.3354/esr00251] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
39
|
Bailey H, Mate BR, Palacios DM, Irvine L, Bograd SJ, Costa DP. Behavioural estimation of blue whale movements in the Northeast Pacific from state-space model analysis of satellite tracks. ENDANGER SPECIES RES 2009. [DOI: 10.3354/esr00239] [Citation(s) in RCA: 172] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
40
|
Milne E, Royle JA, de Klerk NH, Blair E, Bailey H, Cole C, Attia J, Scott RJ, Armstrong BK. Fetal growth and risk of childhood acute lymphoblastic leukemia: results from an Australian case-control study. Am J Epidemiol 2009; 170:221-8. [PMID: 19478236 DOI: 10.1093/aje/kwp117] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The relation between intrauterine growth and risk of childhood acute lymphoblastic leukemia was investigated in an Australian population-based case-control study that included 347 cases and 762 controls aged <15 years recruited from 2003 to 2006. Information on proportion of optimal birth weight, a measure of the appropriateness of fetal growth, was collected from mothers by questionnaire. Data were analyzed by using logistic regression. Risk of acute lymphoblastic leukemia was positively associated with proportion of optimal birth weight; the odds ratio for a 1-standard-deviation increase in proportion of optimal birth weight was 1.18 (95% confidence interval: 1.04, 1.35) after adjustment for the matching variables and potential confounders. This association was also present among children who did not have a high birth weight, suggesting that accelerated growth, rather than high birth weight per se, is associated with risk of acute lymphoblastic leukemia. Similar associations between proportion of optimal birth weight and acute lymphoblastic leukemia were observed for both sexes and across age groups and leukemia subtypes. Results of this study confirm earlier findings of a positive association between rapidity of fetal growth and subsequent risk of acute lymphoblastic leukemia in childhood, and they are consistent with a role for insulin-like growth factors in the causal pathway.
Collapse
Affiliation(s)
- E Milne
- Centre for Child Health Research, Telethon Institute for Child Health Research, University of Western Australia, Perth, Western Australia, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ninan JA, Bailey H, Kolesar J, Marnocha R, Eickhoff J, Wright J, Espinoza-Delgado I, Alberti D, Wilding G, Schelman W. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2531] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2531 Background: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an oral histone deacytlase (HDAC) inhibitor that has anti-tumor activity in hematologic malignancies and advanced solid tumors. Vorinostat has been postulated to act synergistically with bortezomib at the level of aggresome inhibition with creation of reactive oxygen species. We previously conducted a study of this combination with once-daily dosing of vorinostat with bortezomib (Step A). This study (Step B) was conducted to evaluate twice daily dosing of vorinostat during administration of bortezomib to determine safety and efficacy, pharmacokinetics, and activity this combination. Methods: This study used standard eligibility criteria except patients must have had no prior bortezomib. The treatment plan initially consisted of vorinostat given orally twice daily on days 1–14 with bortezomib IV on days 1, 4, 8, and 11 of a 21 day cycle. Two DLTs (elevated ALT and fatigue) were observed at level 1, and the protocol was amended to administer vorinostat twice daily on days 1–4 and 8–11. Starting dose was vorinostat 200 mg and bortezomib 1 mg/m2. RECIST was used to measure response. Results: 29 pts have been enrolled; 13 men and 16 women. Tumor types include: Prostate (1), Colorectal (3), Pancreatic (6), Sarcoma (7), Biliary (1), Thymus (1), GIST (2), Mesothelioma (1), ovarian (1), Neuroendocrine (1), Lung (1), Head and Neck (1), Breast (2), and Cervical (1). Grade 3–4 toxicities possibly related to SAHA at any dose level were as follows: thrombocytopenia (5), fatigue (3), increased ALT (1), elevated INR (1), anemia, (1), hypotension (1), diarrhea (3), anorexia (1), dizziness (1), nausea/vomiting (1), and hypoalbuminemia (1). The only dose limiting toxicities included elevated ALT (1), fatigue (1). There were two deaths but neither was felt to be related to the drug. The MTD for Step B was established at vorinostat 300 mg BID and bortezomib 1.3 mg/m2. Conclusions: The MTD for Step B was established at vorinostat 300 mg BID and bortezomib 1.3 mg/m2. Subjective evidence of clinical activity has been observed in patients with refractory solid tumors. These studies were supported by NCI, UO1, CA062491, SAIC 25XS097, and 1ULRR025011. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Ninan
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - H. Bailey
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - J. Kolesar
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - R. Marnocha
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - J. Eickhoff
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - J. Wright
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - I. Espinoza-Delgado
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - D. Alberti
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - G. Wilding
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| | - W. Schelman
- UW Carbone Comprehensive Cancer Center, Madison, WI; National Cancer Institute, Bethesda, MD
| |
Collapse
|
42
|
|
43
|
Atkinson RJA, Bailey H, Naylor E. Some laboratory methods for recording and displaying temporal patterns of locomotor activity in marine animals. ACTA ACUST UNITED AC 2009. [DOI: 10.1080/10236247409378495] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Attia S, Eickhoff J, Holen KD, Bailey H, Alberti D, Wilding G, Liu G. Phase I study of fixed-dose rate (FDR) gemcitabine with capecitabine in advanced solid malignancies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Wiler JL, Bailey H, Madsen TE. The Need for Emergency Medicine Resident Training in Forensic Medicine. Ann Emerg Med 2007; 50:733-8. [PMID: 17498846 DOI: 10.1016/j.annemergmed.2007.02.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2006] [Revised: 01/22/2007] [Accepted: 02/26/2007] [Indexed: 11/18/2022]
Affiliation(s)
- Jennifer L Wiler
- Department of Emergency Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
| | | | | |
Collapse
|
46
|
Mercer P, Bailey H, Cook P. Perceptions, attitudes and opinions of general dental practitioners and dental nurses to the provision of lifelong learning for the dental team. Br Dent J 2007; 202:747-53. [PMID: 17589462 DOI: 10.1038/bdj.2007.540] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2006] [Indexed: 11/08/2022]
Abstract
This paper reports on a survey of the attitudes of general dental practitioners (GDPs) and dental nurses to continuing education. This has become the subject of increased policy attention in recent years. The Adult Dental Health Survey of 1998 indicated that in order to meet the increase in requirements for the provision of Dental Health Services in the UK the Professions Complementary to Dentistry (PCDs) would be required to play a greater role in the delivery of dental services. In 2001, the Government undertook a review of the dental workforce, with a remit to look at ways to modernise the education and training system for dentists and the other members of the dental team.
Collapse
Affiliation(s)
- P Mercer
- Department for NHS Postgraduate Medical and Dental Education, University of Leeds, Leeds, UK.
| | | | | |
Collapse
|
47
|
Hudson E, Johns C, Hanna L, Brewster A, Macbeth F, Bailey H, Lester J. 33 Radical radiotherapy for non small cell lung cancer (NSCLC): can chemotherapy make the untreatable treatable? Lung Cancer 2007. [DOI: 10.1016/s0169-5002(07)70359-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Shahin MS, Braly P, Rose P, Malpass T, Bailey H, Alvarez RD, Hodge J, Bowen C, Buller R. A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5562] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5562 Background: Kinesin spindle protein (KSP) is required for mitotic spindle bipolarity and cell cycle progression. Ispinesib (ISP), a selective KSP inhibitor, blocks assembly of the mitotic spindle leading to cell cycle arrest and cell death. Methods: This was a phase II study to determine the effectiveness of ISP in patients (pts) with platinum/taxane resistant or refractory ovarian cancer. Pts with progression during, or recurrence < 6 months after prior platinum/taxane therapy, ECOG status 0–2, and CA-125 > 40 U/ml were eligible. ISP was given as a 1 hr IV infusion of 18 mg/m2 Q 21 days. A 2-stage Green-Dahlberg design was employed. In Stage I, 20 evaluable pts were enrolled. If there were no CA-125 responses (Rustin criteria), the study was to be stopped. If > 1 CA-125 responses were seen, 15 more pts were to be enrolled in Stage 2. Overall response was defined by pts who achieved both CA-125 and RECIST criteria. Results: 22 pts with carboplatin/taxane resistant (9) or refractory disease (13) were enrolled: median age = 63 (43–80); 21 were Caucasian; median no. of cycles = 2 (1 - >16). All pts were evaluable for CA-125 assessment. The best CA-125 response was SD in 10 pts (45%); 12 pts had PD (55%). The best radiographic response was a confirmed PR lasting > 30 weeks in one pt who also met CA-125 progression criteria (5%); 5 pts (26%) had SD; and 13 pts (68%) had PD. The most common AEs, in decreasing order, were neutropenia, fatigue, anemia, leukopenia, thrombocytopenia, diarrhea, nausea, vomiting, and decreased appetite. The most frequent Gr 3/4 AE was neutropenia. Conclusions: This study was terminated after Stage I as the CA-125 response criterion to progress to Stage II was not met. One confirmed radiographic partial response was observed. ISP was well tolerated with an acceptable safety profile. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. S. Shahin
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - P. Braly
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - P. Rose
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - T. Malpass
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - H. Bailey
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - R. D. Alvarez
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - J. Hodge
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - C. Bowen
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| | - R. Buller
- Abington Memorial Hospital, Abington, PA; Hematology Oncology Specialists, Covington, LA; Cleveland Clinic, Cleveland, OH; Virginia Mason Medical Center, Seattle, WA; University of Wisconsin Hospital and Clinics, Madison, WI; UAB, Birmingham, AL; GlaxoSmithKline, Research Triangle Park, NC
| |
Collapse
|
49
|
Schelman WR, Kolesar J, Schell K, Marnocha R, Eickhoff J, Alberti D, Wilding G, Bailey H. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3573] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3573 Background: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase (HDAC) inhibitor that has anti- tumor activity in hematologic malignancies and advanced solid tumors. Based on studies showing that HDAC inhibitors increase the activity of the 26S proteasome, vorinostat has been postulated to act synergistically with bortezomib. This study was conducted to determine the toxicities and efficacy of vorinostat with bortezomib. Correlative studies included pharmacokinetics and the effects of vorinostat/bortezomib on cell cycle, proteasome inhibition, histone acetylation, gene expression and apoptosis. Methods: This study used standard eligibility criteria except pts must have had no prior bortezomib. The treatment plan consisted of vorinostat given orally on days 1–14 with bortezomib IV on days 1, 4, 8 and 11 of a 21-day cycle. Starting dose (Step A, level 1) was once-daily vorinostat (400 mg) and bortezomib (0.7 mg/m2). Step B consisted of twice-daily dosing of vorinostat (200mg) with bortezomib at MTD established in Step A. RECIST was used to measure response. Effects on G2/M-phase arrest in buccal mucosa cells (BMC) were measured using flow cytometry. Samples were collected on days 1 and 9, at 0, 2 and 4 hr following treatment. Results: 22 pts have been enrolled; 14 men, 8 women. Tumor types: 5 sarcoma, 5 colorectal, 3 pancreatic, 2 lung, 1 breast, 1 ovarian, 1 bladder, 1 gastric, 1 germ cell, 1 mesothelioma, 1 GIST. Grade 3–4 toxicities at least possibly related to vorinostat at any dose level were as follows: fatigue (3), n/v (1), thrombocytopenia (1), and hyponatremia (1). One pt was unevaluable. DLTs included fatigue (3), hyponatremia (1) and elevated ALT (1). The MTD for Step A was established at vorinostat 400mg daily and bortezomib 1.3 mg/m2. One pt with refractory soft tissue sarcoma had a PR > 9 mo. There was no effect on cell cycle arrest observed with vorinostat in BMCs. Conclusions: The MTD for Step A was established at vorinostat 400mg daily and bortezomib 1.3 mg/m2. Accrual continues at Step B, dose level 1. Subjective and objective evidence of clinical activity has been observed in pts with refractory solid tumors. (Supported by NCI grant UO1 CA062491, NCI SAIC contract 25XS097 and GCRC M01 RR03186.) No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - J. Kolesar
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - K. Schell
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - R. Marnocha
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - J. Eickhoff
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - D. Alberti
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - G. Wilding
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| | - H. Bailey
- Univ of Wisconsin Hosp and Clinics, Madison, WI
| |
Collapse
|
50
|
Hudson E, Powell J, Mukherjee S, Crosby TDL, Brewster AE, Maughan TS, Bailey H, Lester JF. Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer 2007; 96:708-11. [PMID: 17299393 PMCID: PMC2360086 DOI: 10.1038/sj.bjc.6603611] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Primary small cell oesophageal carcinoma (SCOC) is rare, prognosis is poor and there is no established optimum treatment strategy. It shares many clinicopathologic features with small cell carcinoma of the lung; therefore, a similar staging and treatment strategy was adopted. Sixteen cases referred to Velindre hospital between 1998 and 2005 were identified. Patients received platinum-based combination chemotherapy if appropriate. Those with limited disease (LD) received radical radiotherapy (RT) to all sites of disease on completion of chemotherapy. Median survival of all patients was 13.2 months. Median survival of patients with LD was significantly longer than those with extensive disease (24.4 vs 9.1 months, P=0.034). This is one of the largest single institution series in the world literature. Combined modality therapy using platinum-based combination chemotherapy and radical RT may allow a nonsurgical approach to management, avoiding the morbidity of oesophagectomy. Prophylactic cranial irradiation is controversial, and should be discussed on an individual basis.
Collapse
Affiliation(s)
- E Hudson
- Velindre Hospital, Velindre Road, Whitchurch, Cardiff, UK.
| | | | | | | | | | | | | | | |
Collapse
|